KD01
/ Wuhan Kaidejino Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 14, 2024
The Safety, Tolerability, and Efficacy of KD01 in Cervical Malignancies
(clinicaltrials.gov)
- P1 | N=45 | Recruiting | Sponsor: Tongji Hospital
New P1 trial • Oncolytic virus • Cervical Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1